Evommune Inc. is set to make its debut on the New York Stock Exchange on November 6, 2025, under the symbol "EVMN."
This clinical-stage biotechnology company, developing innovative therapies that target key drivers of chronic inflammatory diseases, is offering 9.38 million shares of its common stock at an initial public offering price of $16 per share. The offering is scheduled to close on November 7, 2025, and is expected to generate gross proceeds of $150 million.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.